Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308500718> ?p ?o ?g. }
- W4308500718 endingPage "1431" @default.
- W4308500718 startingPage "1426" @default.
- W4308500718 abstract "Borderline resectable adenocarcinoma of the pancreas involves the major vascular structures adjacent to the pancreas and has traditionally led to poor resection rates and survival. Newer chemotherapy regimens have demonstrated improved response and resection rates. We performed a retrospective review of borderline resectable pancreatic cancers who presented to a community cancer program to determine the effect of neoadjuvant chemotherapy to improve resection rates and overall survival.Records of all patients diagnosed with adenocarcinoma of the pancreas from January 1, 2015 to December 31, 2019 were reviewed to determine stage at presentation, resectablility status, treatment methods, surgical resection and survival. Borderline resectable status was determined by preoperative imaging in agreement with published criteria from the National Comprehensive Cancer Network (NCCN) Guidelines 2.2021. Data was collected and analyzed by standard t-test. This study was approved by the institution's IRB.During this time period 322 patients were diagnosed with ductal adenocarcinoma of the pancreas of which 151 (47%) were unresectable, 31 (10%) were locally advanced, 70 (22%) were borderline resectable, and 69 (21%) were resectable at the time of presentation. 36 (51%) of the borderline resectable patients underwent neoadjuvant chemotherapy at our institution with either FOLFIRINOX or gemcitibine/nab-Paclitaxel regimens and served as the basis for this analysis. After neoadjuvant chemotherapy 24 (68%) of the borderline-resectable patients were deemed suitable for surgical exploration. At exploration, 15 (64%) were resected with 9 (60%) achieving margin-free resection on final pathology. The overall survival of those that underwent resection was increased by 19.6 months compared to those that did not undergo surgery (35.4 versus 15.8 mos, p < 0.01). Overall morbidity after resection was 46% (33% class 1 or 2, 13% class 3) with 0% mortality at 90 days.Use of neoadjuvant chemotherapy for borderline resectable adenocarcinoma of the pancreas results in improved resection rates and overall survival in resected patients. This management strategy for ductal adenocarcinoma of the pancreas is safe and feasible in a community-based cancer program." @default.
- W4308500718 created "2022-11-12" @default.
- W4308500718 creator A5026582896 @default.
- W4308500718 creator A5045118133 @default.
- W4308500718 creator A5051948376 @default.
- W4308500718 creator A5068927470 @default.
- W4308500718 creator A5078309574 @default.
- W4308500718 creator A5087588161 @default.
- W4308500718 date "2022-12-01" @default.
- W4308500718 modified "2023-10-18" @default.
- W4308500718 title "Improved outcomes for borderline resectable adenocarcinoma of the pancreas after neoadjuvant chemotherapy in a community cancer center" @default.
- W4308500718 cites W2008890375 @default.
- W4308500718 cites W2044557172 @default.
- W4308500718 cites W2067690154 @default.
- W4308500718 cites W2096998881 @default.
- W4308500718 cites W2135164357 @default.
- W4308500718 cites W2160029372 @default.
- W4308500718 cites W2177644038 @default.
- W4308500718 cites W2588671547 @default.
- W4308500718 cites W2737354131 @default.
- W4308500718 cites W2761846603 @default.
- W4308500718 cites W2765938006 @default.
- W4308500718 cites W2883743469 @default.
- W4308500718 cites W2891625981 @default.
- W4308500718 cites W2899636950 @default.
- W4308500718 cites W2926499479 @default.
- W4308500718 cites W2974255367 @default.
- W4308500718 cites W3008190574 @default.
- W4308500718 cites W3020874141 @default.
- W4308500718 cites W3119005666 @default.
- W4308500718 cites W3127405115 @default.
- W4308500718 cites W4210621479 @default.
- W4308500718 cites W4233517955 @default.
- W4308500718 doi "https://doi.org/10.1016/j.amjsurg.2022.10.027" @default.
- W4308500718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36372580" @default.
- W4308500718 hasPublicationYear "2022" @default.
- W4308500718 type Work @default.
- W4308500718 citedByCount "0" @default.
- W4308500718 crossrefType "journal-article" @default.
- W4308500718 hasAuthorship W4308500718A5026582896 @default.
- W4308500718 hasAuthorship W4308500718A5045118133 @default.
- W4308500718 hasAuthorship W4308500718A5051948376 @default.
- W4308500718 hasAuthorship W4308500718A5068927470 @default.
- W4308500718 hasAuthorship W4308500718A5078309574 @default.
- W4308500718 hasAuthorship W4308500718A5087588161 @default.
- W4308500718 hasConcept C121608353 @default.
- W4308500718 hasConcept C126322002 @default.
- W4308500718 hasConcept C141071460 @default.
- W4308500718 hasConcept C143998085 @default.
- W4308500718 hasConcept C146357865 @default.
- W4308500718 hasConcept C151730666 @default.
- W4308500718 hasConcept C2776694085 @default.
- W4308500718 hasConcept C2777148230 @default.
- W4308500718 hasConcept C2778292576 @default.
- W4308500718 hasConcept C2778494859 @default.
- W4308500718 hasConcept C2778764654 @default.
- W4308500718 hasConcept C2780210213 @default.
- W4308500718 hasConcept C2780259306 @default.
- W4308500718 hasConcept C2781182431 @default.
- W4308500718 hasConcept C526805850 @default.
- W4308500718 hasConcept C530470458 @default.
- W4308500718 hasConcept C61434518 @default.
- W4308500718 hasConcept C71924100 @default.
- W4308500718 hasConcept C86803240 @default.
- W4308500718 hasConceptScore W4308500718C121608353 @default.
- W4308500718 hasConceptScore W4308500718C126322002 @default.
- W4308500718 hasConceptScore W4308500718C141071460 @default.
- W4308500718 hasConceptScore W4308500718C143998085 @default.
- W4308500718 hasConceptScore W4308500718C146357865 @default.
- W4308500718 hasConceptScore W4308500718C151730666 @default.
- W4308500718 hasConceptScore W4308500718C2776694085 @default.
- W4308500718 hasConceptScore W4308500718C2777148230 @default.
- W4308500718 hasConceptScore W4308500718C2778292576 @default.
- W4308500718 hasConceptScore W4308500718C2778494859 @default.
- W4308500718 hasConceptScore W4308500718C2778764654 @default.
- W4308500718 hasConceptScore W4308500718C2780210213 @default.
- W4308500718 hasConceptScore W4308500718C2780259306 @default.
- W4308500718 hasConceptScore W4308500718C2781182431 @default.
- W4308500718 hasConceptScore W4308500718C526805850 @default.
- W4308500718 hasConceptScore W4308500718C530470458 @default.
- W4308500718 hasConceptScore W4308500718C61434518 @default.
- W4308500718 hasConceptScore W4308500718C71924100 @default.
- W4308500718 hasConceptScore W4308500718C86803240 @default.
- W4308500718 hasIssue "6" @default.
- W4308500718 hasLocation W43085007181 @default.
- W4308500718 hasLocation W43085007182 @default.
- W4308500718 hasOpenAccess W4308500718 @default.
- W4308500718 hasPrimaryLocation W43085007181 @default.
- W4308500718 hasRelatedWork W3106129438 @default.
- W4308500718 hasRelatedWork W3120139350 @default.
- W4308500718 hasRelatedWork W4229863258 @default.
- W4308500718 hasRelatedWork W4245024017 @default.
- W4308500718 hasRelatedWork W4313389313 @default.
- W4308500718 hasRelatedWork W4318192576 @default.
- W4308500718 hasRelatedWork W4318318110 @default.
- W4308500718 hasRelatedWork W4318321277 @default.
- W4308500718 hasRelatedWork W4319232702 @default.
- W4308500718 hasRelatedWork W4380632434 @default.